Vitae Pharmaceuticals Company Profile (NASDAQ:VTAE)

About Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals logoVitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VTAE
  • CUSIP: N/A
  • Web: www.vitaepharma.com
Average Prices:
  • 50 Day Moving Avg: $18.81
  • 200 Day Moving Avg: $11.50
  • 52 Week Range: $4.08 - $21.03
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.35
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -13,954.35%
  • Return on Equity: -65.51%
  • Return on Assets: -59.63%
Debt:
  • Current Ratio: 12.83%
  • Quick Ratio: 12.83%
Misc:
  • Average Volume: 1.05 million shs.
  • Beta: 0.62
 

Frequently Asked Questions for Vitae Pharmaceuticals (NASDAQ:VTAE)

What is Vitae Pharmaceuticals' stock symbol?

Vitae Pharmaceuticals trades on the NASDAQ under the ticker symbol "VTAE."

How were Vitae Pharmaceuticals' earnings last quarter?

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) posted its quarterly earnings results on Wednesday, August, 3rd. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.05. Vitae Pharmaceuticals had a negative return on equity of 65.51% and a negative net margin of 13,954.35%. The company's revenue for the quarter was down 98.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.45) EPS. View Vitae Pharmaceuticals' Earnings History.

Where is Vitae Pharmaceuticals' stock going? Where will Vitae Pharmaceuticals' stock price be in 2017?

6 brokers have issued 12-month price objectives for Vitae Pharmaceuticals' shares. Their predictions range from $21.00 to $23.00. On average, they anticipate Vitae Pharmaceuticals' stock price to reach $21.67 in the next twelve months. View Analyst Ratings for Vitae Pharmaceuticals.

Who are some of Vitae Pharmaceuticals' key competitors?

How do I buy Vitae Pharmaceuticals stock?

Shares of Vitae Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vitae Pharmaceuticals stock cost?

One share of Vitae Pharmaceuticals stock can currently be purchased for approximately $21.00.

Analyst Ratings

Consensus Ratings for Vitae Pharmaceuticals (NASDAQ:VTAE) (?)
Ratings Breakdown: 6 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $21.67 (3.17% upside)

Analysts' Ratings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
9/15/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$17.00 -> $21.00N/AView Rating Details
9/14/2016WedbushDowngradeOutperform -> Neutral$21.00 -> $23.00N/AView Rating Details
9/14/2016Stifel NicolausDowngradeBuy -> Hold$21.00N/AView Rating Details
9/11/2016Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
8/4/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Earnings by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Earnings History by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q2($0.41)($0.36)$0.05 millionViewListenView Earnings Details
5/10/2016Q1($0.51)($0.44)$0.09 million$0.05 millionViewListenView Earnings Details
3/3/2016Q415($0.62)($0.52)$0.14 million$0.09 millionViewListenView Earnings Details
11/5/2015Q315($0.48)($0.60)$0.18 million$0.18 millionViewListenView Earnings Details
8/4/2015Q215($0.45)($0.45)$0.09 million$0.16 millionViewListenView Earnings Details
5/12/2015Q115($0.33)($0.47)$0.16 million$0.15 millionViewListenView Earnings Details
3/31/2015Q414($0.45)($0.40)$0.19 million$0.16 millionViewListenView Earnings Details
11/12/2014Q3($0.13)($1.03)$6.39 million$6.18 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vitae Pharmaceuticals (NASDAQ:VTAE)
2017 EPS Consensus Estimate: ($1.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Insider Ownership Percentage: 14.80%
Institutional Ownership Percentage: 72.58%
Insider Trades by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Institutional Ownership by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Insider Trades by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2016Adage Capital Partners Gp, L.LMajor ShareholderSell1,025,000$20.85$21,371,250.00View SEC Filing  
9/14/2016Jeffrey S HatfieldCEOSell50,000$20.81$1,040,500.00View SEC Filing  
3/21/2016Donald J Hayden JrDirectorSell16,130$7.42$119,684.60View SEC Filing  
12/29/2015Donald J. Hayden, Jr.DirectorSell16,130$18.00$290,340.00View SEC Filing  
12/23/2015Jeffrey S. HatfieldCEOSell22,524$17.00$382,908.00View SEC Filing  
9/21/2015Donald J. Hayden, Jr.DirectorSell16,130$17.00$274,210.00View SEC Filing  
9/29/2014Peter BarrettDirectorBuy37,500$8.00$300,000.00View SEC Filing  
9/29/2014Venrock Management Iii LlcMajor ShareholderBuy772,333$8.00$6,178,664.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vitae Pharmaceuticals (NASDAQ:VTAE)
Latest Headlines for Vitae Pharmaceuticals (NASDAQ:VTAE)
Source:

Social

Chart

Vitae Pharmaceuticals (VTAE) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff